Latest news for oOh media (OTC:OMLAF) Stock

OOh media operates a network of out-of-home advertising sites with a commanding approximately 40% share of the Australian market, and also has a big presence in New Zealand. It boasts a diverse portfolio of locations to service the needs of out-of-home marketers, and is particularly strong in the roadside billboard, street furniture and rail, and retail (shopping malls) segments. OOh!media offers these services by entering into space lease arrangements with owners of out-of-home sites, and extracting margins on those lease concessions from firms advertising on those sites. oOh!media is effectively an intermediary allowing site owners to monetize their visible space in high-traffic areas.

oOh media Ltd

In the last three months, 45 analysts have published ratings on Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">22</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $224.55, a high estimate of $310.00, and a low estimate of $24.86. This upward trend is evident, with the current average reflecting a 2.75% increase from the previous average price target of $218.54.
<img src="https://www.benzinga.com/files/images/story/2024/1728651667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Tesla is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$236.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Toni Sacconaghi</td>
<td>Bernstein</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$24.86</td>
<td>$24.86</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$224.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$254.00</td>
<td>$254.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$254.00</td>
<td>$254.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Sell</td>
<td>$153.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Edison Yu</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$295.00</td>
<td>-</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$24.86</td>
<td>$24.86</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$224.00</td>
<td>$227.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Bill Selesky</td>
<td>Argus Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$286.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Jennifer Liang</td>
<td>KGI Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$236.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$134.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andres Sheppard</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Pierre Ferragu</td>
<td>New Street Research</td>
<td>Announces</td>
<td>Neutral</td>
<td>$225.00</td>
<td>-</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$215.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Craig Irwin</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Itay Michaeli</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$258.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Raises</td>
<td>Sell</td>
<td>$24.86</td>
<td>$22.86</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Sell</td>
<td>$134.00</td>
<td>$134.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tesla. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tesla compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Tesla's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Tesla's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TSLA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tesla analyst ratings.</a>
<h2>About Tesla</h2>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi-truck. Tesla also plans to begin selling more affordable vehicles, and a sports car. Global deliveries in 2023 were a little over 1.8 million vehicles. The company also sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
<h3>Tesla: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Tesla's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Tesla's net margin is impressive, surpassing industry averages. With a net margin of 5.8%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tesla's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.26%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Tesla's ROA stands out, surpassing industry averages. With an impressive ROA of 1.33%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Tesla's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TSLA

The Analyst Landscape: 45 Takes On Tesla

Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Mirum Pharmaceuticals and provided 12-month price targets. The average target is $60.4, accompanied by a high estimate of $66.00 and a low estimate of $44.00. This current average reflects an increase of 6.71% from the previous average price target of $56.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1728651656_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Mirum Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Mirum Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Mirum Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Mirum Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MIRM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Mirum Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Mirum Pharmaceuticals: A Closer Look</h2>
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
<h3>Financial Insights: Mirum Pharmaceuticals</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Mirum Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 107.68% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Mirum Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -31.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Mirum Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.63%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Mirum Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of -3.75%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.38, Mirum Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MIRM

Analyst Expectations For Mirum Pharmaceuticals's Future

Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.6, a high estimate of $17.00, and a low estimate of $12.00. This current average has decreased by 4.23% from the previous average price target of $14.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1728651630_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Sutro Biopharma's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sutro Biopharma. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sutro Biopharma compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sutro Biopharma's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sutro Biopharma's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sutro Biopharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Sutro Biopharma: A Closer Look</h2>
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
<h3>Understanding the Numbers: Sutro Biopharma's Finances</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Sutro Biopharma displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 146.89%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sutro Biopharma's net margin excels beyond industry benchmarks, reaching -186.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -38.38%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sutro Biopharma's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -10.76%, the company showcases efficient use of assets and strong financial health.
Debt Management: Sutro Biopharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.17.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STRO

Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights

Qualcomm's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NYSE">QCOM</a>) short percent of float has risen 7.94% since its last report. The company recently reported that it has 25.68 million shares sold short, which is 2.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Qualcomm Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728651626_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Qualcomm has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Qualcomm's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Qualcomm's peer group average for short interest as a percentage of float is 4.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

QCOM

Looking Into Qualcomm's Recent Short Interest

Huntington Bancshares's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NYSE">HBAN</a>) short percent of float has fallen 17.98% since its last report. The company recently reported that it has 27.87 million shares sold short, which is 2.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Huntington Bancshares Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728651621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Huntington Bancshares has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Huntington Bancshares's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Huntington Bancshares's peer group average for short interest as a percentage of float is 3.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HBAN

(HBAN) - Analyzing Huntington Bancshares's Short Interest

In the last three months, 13 analysts have published ratings on Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $292.92, a high estimate of $325.00, and a low estimate of $260.00. This current average reflects an increase of 1.77% from the previous average price target of $287.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1728651619_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Tractor Supply. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Oliver Wintermantel</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$315.00</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Oliver Wintermantel</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>John Lawrence</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$293.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$295.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tractor Supply. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tractor Supply compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tractor Supply's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tractor Supply's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TSCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tractor Supply analyst ratings.</a>
<h2>Delving into Tractor Supply's Background</h2>
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,254 of its namesake banners in 49 states, including 81 Orscheln Farm and Home stores (rebranded as Tractor Supply), along with 205 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities, as opposed to urban and suburban areas. In fiscal 2023, revenue consisted primarily of livestock, equine &amp; agriculture (27%), companion animal (25%), and seasonal &amp; recreation (22%).
<h3>Tractor Supply: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Tractor Supply's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 1.48%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Tractor Supply's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.01% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Tractor Supply's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Tractor Supply's ROA excels beyond industry benchmarks, reaching 4.4%. This signifies efficient management of assets and strong financial health.
Debt Management: Tractor Supply's debt-to-equity ratio is below the industry average at 2.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TSCO

Forecasting The Future: 13 Analyst Projections For Tractor Supply

American Finl Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) short percent of float has risen 27.52% since its last report. The company recently reported that it has 998 thousand shares sold short, which is 1.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>American Finl Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728651615_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for American Finl Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing American Finl Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, American Finl Gr's peer group average for short interest as a percentage of float is 1.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into American Finl Gr's Recent Short Interest

Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sociedad Quimica Y Minera and provided 12-month price targets. The average target is $41.6, accompanied by a high estimate of $55.00 and a low estimate of $35.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.69%. 
<img src="https://www.benzinga.com/files/images/story/2024/1728651609_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Sociedad Quimica Y Minera among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lucas Ferreira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alejandro Demichelis</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$62.80</td>
</tr>
<tr>
<td>Isabella Simonato</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$38.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Andres Castanos Mollor</td>
<td>Berenberg</td>
<td>Announces</td>
<td>Hold</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Corinne Blanchard</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$36.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sociedad Quimica Y Minera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sociedad Quimica Y Minera compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sociedad Quimica Y Minera's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sociedad Quimica Y Minera's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SQM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sociedad Quimica Y Minera analyst ratings.</a>
<h2>About Sociedad Quimica Y Minera</h2>
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM is developing a hard rock lithium project in Australia and expanding its lithium refining assets in China.
<h3>Sociedad Quimica Y Minera: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Sociedad Quimica Y Minera's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -36.95%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Sociedad Quimica Y Minera's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sociedad Quimica Y Minera's ROE excels beyond industry benchmarks, reaching 4.46%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.0%, the company showcases effective utilization of assets.
Debt Management: Sociedad Quimica Y Minera's debt-to-equity ratio is below the industry average. With a ratio of 0.91, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Sociedad Quimica Y Minera

Wells Fargo analyst Zachary Fadem maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Overweight and raises the price target from $295 to $325.

News

Price Target

Wells Fargo Maintains Overweight on Tractor Supply, Raises Price Target to $325

On Friday, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) said it is negotiating with Clayton Dubilier &amp; Rice (CD&amp;R) to potentially sell a 50% controlling stake in Opella, its <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">consumer healthcare business</a>.
According to the Bloomberg report, the <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-10/cd-r-said-near-15-billion-deal-for-sanofi-consumer-health-unit" rel="noreferrer noopener">deal</a> could be valued at about 15 billion euros ($16.4 billion), making it one of the largest European transactions this year. Sanofi is likely to retain a minority stake in the Opella business.
In October 2023,&nbsp;Sanofi announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">pipeline and cut costs</a>.
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
As per a Bloomberg report, two private equity firms,&nbsp;Clayton Dubilier &amp; Rice and&nbsp;PAI Partners, made separate bids for Sanofi&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41021471/private-equity-firms-circle-sanofis-consumer-health-business-amid-potential-spinoff" rel="noreferrer noopener">consumer health division</a>.
If these <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-10-11-06-30-00-2961805" rel="noreferrer noopener">discussions</a> lead to a positive outcome, any agreement would be conditional on completing the necessary social processes.
Further updates on the potential separation of Opella will be provided in due course when a decision is made.
Headquartered in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 manufacturing sites and four research and innovation centers.
With a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax, Opella is the world&#8217;s third-largest company in the over-the-counter and vitamins, minerals, and supplements market, serving over 500 million consumers worldwide.
Opella&#8217;s journey to independence aligns with Sanofi&#8217;s strategy to focus on innovative medicines and vaccines.
Opella already operates today as a standalone business unit within Sanofi, with dedicated R&amp;D, production, and digital resources.
Goldman Sachs Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and&nbsp;Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring&nbsp;Sanofi&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39755459/sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-6-5b-financing" rel="noreferrer noopener">consumer health division</a>.
Last year, Sanofi initiated talks with Rothschild &amp; Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35823034/major-buyout-firms-eye-sanofis-consumer-health-division-spinoff-valued-over-20b" rel="noreferrer noopener">over $20 billion</a>.&nbsp;
Other potential bidders who <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39502197/sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-c" rel="noreferrer noopener">circled the deal include</a> Advent International, Blackstone Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), CVC Capital Partners Plc, and&nbsp;TPG Inc.
Separating the consumer health unit would align Sanofi with industry peers.&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) have also divested their consumer divisions&nbsp;Haleon Plc&nbsp;
(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), respectively, to focus on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">next-generation therapies</a>.
Price Action: At last check on Friday, SNY stock was up 0.11% at $54.83 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41289207/wells-fargo-q3-earnings-lower-profit-on-squeezed-interest-income-but-investment-banking-fees-provid" target="_blank" rel="noreferrer noopener">Wells Fargo Q3 Earnings: Lower Profit On Squeezed Interest Income, But Investment Banking Fees Provide Cushion</a></li>
</ul>
Image by HJBC via Shutterstock

Biotech

Large Cap

Health Care

Media

General

KVUE

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice

WIIM

STLA

Stellantis shares are trading lower after the company said CEO Carlos Tavares would retire in 2026.

<a href="https://event.webcasts.com/starthere.jsp?ei=1687070&amp;tp_key=41ca140a1b" title="https://event.webcasts.com/starthere.jsp?ei=1687070&amp;tp_key=41ca140a1b">https://event.webcasts.com/starthere.jsp?ei=1687070&amp;tp_key=41ca140a1b</a>

Guidance

JPMorgan CFO Says Expects Net Interest Income Ex-markets To Be At $87B For 2025

CLOV

Clover Health shares are trading higher after the Centers for Medicare and Medicaid Services increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025.

ALCE

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

LYFT

UBER

Uber and Lyft shares are trading higher in reaction to Tesla announcing that a rival offering, the Cybercab, will go into production in 2026.

Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW)))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, today announced the official launch of its Mudra Band on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=fbDUWr9BgmRrMtdHVoiw15sazD7ZYh45wDxJCwx9py01VaocW-5iBdQWhIbDjkWfSBATE-GeIIeWhEXw6bRTlQ==">Walmart.com</a> ("Walmart"). This exciting development brings the Company's innovative neural-based gesture control technology to one of the largest retail platforms in the world, making it more accessible to millions of Apple users in the United States.
This launch on Walmart aligns with Wearable Devices' strategic goal of expanding its presence across major U.S. retail platforms. Following the successful introduction of the Mudra Band on Amazon, this move significantly broadens the Company's market reach. By being available on Walmart, Wearable Devices is enabling a wider audience to experience next-level gesture control and enhancing its brand recognition in the U.S. market.
The Mudra Band, designed specifically for Apple Watch, allows users to interact with their Apple devices—such as the iPhone, iPad, Apple TV, and MacBook—using simple hand gestures. By harnessing neural signals and translating them into commands, users can control their devices without needing to touch the screen, providing a seamless and innovative user experience.

WLDS

Wearable Devices Announces The Launch Of Mudra Band For Apple Watch On Walmart.com, Expanding Access To Its Gesture-Controlled Technology

The Bank Of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) shares are trading higher in the premarket session on Friday after its <a href="https://www.benzinga.com/pressreleases/24/10/n41288143/bny-reports-third-quarter-2024-results" target="_blank" rel="noreferrer noopener">third-quarter results</a>.
The finance behemoth reported third-quarter adjusted earnings per share of $1.52 (+20% YoY), <a href="https://www.benzinga.com/earnings">beating the street view of $1.42.</a>
Quarterly revenue of $4.648 billion, an increase of 5% year-over-year, surpassed the analyst consensus of $4.542 billion.
Net interest income rose by 3% YoY, driven mainly by higher yields from the investment securities portfolio and balance sheet expansion, though partially offset by shifts in the deposit mix.
Fee revenue in the quarter grew 5% year over year to $3.404 billion. Investment revenue rose, reflecting&nbsp;a strategic equity loss in 3Q23 and better seed capital investment performance.
Noninterest expense for the quarter stood at $3.1 billion flat YoY, as higher investments and merit increases were offset by efficiency savings and a reduced FDIC assessment. Excluding notable items, it increased 1%.
The Bank of New York Mellon reported average deposits of $285 billion, which increased 9% year over year and remained flat sequentially.
Related: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41236943/higher-fee-income-to-aid-bny-mellons-q3-earnings-subdued-nir-to-hurt" rel="noreferrer noopener">Higher Fee Income to Aid BNY Mellon&#8217;s Q3 Earnings, Subdued NIR to Hurt</a>
The company stated that its third-quarter tier 1 leverage ratio of 6.0% decreased 4 bps year-over-year and increased 19 bps sequentially. Adjusted pre-tax operating margin totaled 33% (vs. 31% a year ago).
As of September-end, CET1 capital was $19.7 billion, and Tier 1 capital was $24.0 billion, up from June-end, due to earnings, partially offset by stock repurchases and dividends.
Dividend: BNY declared a common stock dividend of $0.47 per share, payable on November 1 to shareholders of record <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41288184/bny-declares-dividends" rel="noreferrer noopener">as of the close of business on October 21</a>.
The bank returned $1.08 billion to common shareholders, including $353 million in dividends and $725 million in share repurchases, achieving a total payout ratio of 103% year-to-date.
Also Read: <a target="_blank" href="v" rel="noreferrer noopener">Banks Gear Up For Earnings Season: 15 Top Stock Picks Including Citigroup, Morgan Stanley, And Truist</a>
&#8220;BNY reported strong third quarter results, reflecting growth across our three business segments and consistent execution against our strategic priorities, with assets under custody and/or administration exceeding $50 trillion for the first time,&#8221; commented Robin Vince, President and Chief Executive Officer.
&#8220;Our actions to run our company better, including our ongoing transition to a platforms operating model, are starting to deliver progress toward our medium-term financial targets and additional capacity to reinvest for growth through new and enhanced client solutions,&#8221; added Vince.
Price Action: BK shares are trading higher by 2.07% to $75.99 premarket at the last check Friday.
Photo by JHVEPhoto via Shutterstock

Earnings

Movers

BNY Q3 Earnings: Fee Income Soars 5%, Setting New $50T Record In Assets Under Custody

Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) just unveiled its next <a href="https://www.benzinga.com/topic/artificial-intelligence">wave of AI</a> weaponry, and it's taking aim at none other than Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). 
AMD is gearing up to claim a bigger slice of the AI pie in an AI event packed with hardware reveals, partnerships, and tantalizing hints of future dominance. But can the underdog challenge the reigning champ in AI accelerators?
JPMorgan&#8217;s Harlan Sur remains cautious, sticking with a Neutral rating while highlighting the hefty potential in AMD's AI-focused arsenal.
<h2 class="wp-block-heading">AI Market Outlook: Bigger, Better, Faster</h2>
AMD's AI event wasn't just a product showcase; it was a declaration of intent. The company bumped up its AI accelerator total addressable market (TAM) outlook from $400 billion in 2027 to a massive $500 billion by 2028, thanks to a continued surge in AI model deployments and use cases, Sur noted.
The TAM growth may decelerate as we inch toward 2028, but AMD's strong foothold with its CPUs, GPUs, and DPUs puts it in a prime position to capture more of the AI wave.
The recent ZT Systems acquisition will also help AMD iron out any kinks in production and speed up customer ramp-ups—a clear sign the company is focused on scaling fast, the analyst said.
Read Also: <a href="https://www.benzinga.com//node/41282666">What Happened With AMD Stock Today?</a>
<h2 class="wp-block-heading">MI325X GPU: AMD's AI Champion Steps Into The Ring</h2>
The event's highlight? AMD&#8217;s MI325X, a GPU designed to go head-to-head with Nvidia's H200 HGX in AI training. While the MI325X holds its own in training, it takes the crown in AI inferencing, outpacing Nvidia's H200 by 1.4x. Production shipments start soon, and with the MI350 set for 2025—boasting a 1.8x boost in AI compute performance—AMD is clearly not backing down in its GPU battle with Nvidia.
But, as Sur points out, this race is a marathon, not a sprint. AMD is ramping up, but Nvidia&#8217;s lead still looms large, and capturing market share will take time.
<h2 class="wp-block-heading">Server CPUs: AMD&#8217;s Zen-Fueled Takeover</h2>
AMD isn't leaving its core CPU game behind, either. The company launched its next-gen EPYC processor, codenamed "Turin," built on its Zen 5 architecture. 
With a 40% performance edge over Intel's Granite Rapids, AMD continues to eat up server CPU market share.
Sur noted that AMD&#8217;s server CPU share jumped from 31% to 34% in the first half of 2024, and Turin could drive further gains in the coming quarters.
<h2 class="wp-block-heading">Software, Strategic Partnerships: The Secret Sauce</h2>
Beyond hardware, AMD&#8217;s progress on the software front is crucial. The ROCm 6.2 software stack has shown a 2.4x improvement in AI inference performance—critical for staying competitive in a market where software optimization can be a game-changer. 
Add in deep partnerships with cloud giants like Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), and AMD has the strategic backing to take on the big leagues.
<h2 class="wp-block-heading">The Bottom Line?</h2>
AMD's AI event showcased a tech company ready for battle, but dethroning Nvidia will not be easy.
Sur's price target of $180 by the end of 2025 reflects optimism but caution as AMD's ramp-up in AI accelerators and servers plays out over the next few years.
Keep an eye on AMD stock as it gears up for its biggest AI push yet—this might be a battle worth watching.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/41284533">Nvidia&#8217;s Blackwell Chip Faces AMD&#8217;s MI350 Challenge In 2025: CEO Lisa Su Says, &#8216;Beginning, Not The End Of The AI Race&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Tech

MSFT

NVDA

ORCL

AMD Stock: Can Its AI Strategy Compete With Nvidia? Analyst Predicts Market Share Gains Ahead

Wells Fargo analyst Andrew Bauch downgrades Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) from Overweight to Equal-Weight and lowers the price target from $20 to $18.

Downgrades

FLYW

Wells Fargo Downgrades Flywire to Equal-Weight, Lowers Price Target to $18

Mizuho analyst Vijay Rakesh downgrades Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Outperform to Neutral and lowers the price target from $30 to $13.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

oOh media

News

Latest news for oOh media (OTC:OMLAF) Stock